Clinical trial data and ongoing trials testing novel treatments in NSCLC
| Type | Drug | Trial | Outcomes | Phase/No. |
|---|---|---|---|---|
| CAR-T | EGFR-targeting CAR-T, modified by CXCR5 | NCT05060796, NCT04153799 | 1 (n = 11), 1 (n = 11) | |
| EGFR-targeting CAR-T, knocked-out TGFβ receptor | NCT04976218 | 1 (n = 30) | ||
| MSLN-targeting CAR-T plus anti-PD-1 cells (for mesothelioma) | NCT04577326 | 1 (n = 30) | ||
| MSLN-targeting CAR-T | NCT04489862 | 1 (n = 10) | ||
| PSCA/MUC1/TGFβ/GPC3-targeting CAR-T | NCT03198052 | 1 (n = 30) | ||
| MUC1-targeting CAR-T plus anti-PD-1 cells | NCT03525782 | 1/2 (n = 60) | ||
| MUC1-targeting CAR-T, 3 + 3 dose design | NCT05239143 | 1 (n = 100) | ||
| TCR | KK-LC1-targeting TCR, followed by high dose IL-2 | NCT05483491, NCT03778814 | 1 (n = 42), 1 (n = 30) | |
| MAGE A4/8-targeting TCR | NCT03247309 | 1 (n = 7) | ||
| MAGE A10-targeting TCR | NCT02592577 [83] | 11% PR36% SD | 1 (n = 11) | |
| Neoantigen-targeting TCR (NSCLC not specified) | NCT03412877 | 2 (n = 270 total) | ||
| NY-ESO-1 targeting TCR, followed by low dose IL-2 | NCT02457650 [84] | 25% PR25% SD | 1 (n = 4) | |
| NY-ESO-1 targeting TCR | NCT05296564 | 1 (n = 3) | ||
| KRAS, EGFR, TP53 targeting TCR; followed by IL-2 (NSCLC not specified) | NCT05194735 | 1/2 (n = 180 total) | ||
| mRNA | CEA-targeting RNA-pulsed DCs (NSCLC not specified) | NCT00004604 [85] | 4% CR8% PR12% SD | 1 (n = 24) |
| SOCS1, MUC1, survivin-targeting RNAs | NCT02688686 | 1/2 (n = 30) | ||
| KRAS-targeting RNA | NCT03948763, NCT05202561 | 1 (n = 70), 1 (n = 10) | ||
| NY-ESO-1, MAGEC1/C2, survivin, trophoblast-targeting RNAs (CV9201) | NCT00923312 [86] | 31% SD69% PDmPFS 5.0 momOS 10.8 mo | 1/2 (n = 46) | |
| NY-ESO-1, MAGEC1/C2, MUC1, survivin, 5T4 RNAs (CV9202 or BI1361849) | NCT03164772 [87] (Arm A: mRNA plus durvalumab; Arm B mRNA plus durvalumab plus tremelimumab) | Arm A: ORR 29% Arm B: ORR 11% | 1/2 (n = 62) | |
| NCT01915524 [88] | 4% PR (with pemetrexed)46.2% SD | 1 (n = 26) Terminate | ||
| Personalized neoantigen mRNA | NCT03908671 | 1 (n = 24) |
CAR: chimeric antigen receptor; TCR: T-cell receptor therapy; ORR: overall response rate; mPFS: median progression-free survival; mOS: median overall survival; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; GPC3: phosphatidylinositol proteoglycan 3; MUC1: mucin 1; NSCLC: non-small cell lung cancer; PSCA: prostate stem cell antigen